XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.2
Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)
$ in Thousands
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Total
Balances at Dec. 31, 2023 $ 429,797 $ (908) $ (428,282) $ 607
Balance, shares at Dec. 31, 2023 454,537 4,412        
Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering (80) (80)
Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering, shares   915        
Series B Preferred stock conversions
Series B Preferred stock conversions, shares (119,000) 165        
Stock-based compensation 203 203
Unrealized foreign exchange on intercompany loans (2,130) (2,130)
Translation adjustment 2,140 2,140
Loss for the period (2,946) (2,946)
Balances at Mar. 31, 2024 429,920 (898) (431,228) (2,206)
Balance, shares at Mar. 31, 2024 335,537 5,493        
Balances at Dec. 31, 2023 429,797 (908) (428,282) 607
Balance, shares at Dec. 31, 2023 454,537 4,412        
Unrealized foreign exchange on intercompany loans           (1,626)
Translation adjustment           1,619
Loss for the period           (6,203)
Balances at Jun. 30, 2024 436,399 (915) (434,485) 999
Balance, shares at Jun. 30, 2024 335,537 7,522        
Balances at Mar. 31, 2024 429,920 (898) (431,228) (2,206)
Balance, shares at Mar. 31, 2024 335,537 5,493        
Stock-based compensation 189 189
Unrealized foreign exchange on intercompany loans 504 504
Translation adjustment (521) (521)
Loss for the period (3,257) (3,257)
Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Private Placement, net of expenses 6,290 6,290
Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Private Placement, net of expenses, shares   2,029        
Balances at Jun. 30, 2024 436,399 (915) (434,485) 999
Balance, shares at Jun. 30, 2024 335,537 7,522        
Balances at Dec. 31, 2024 438,211 (891) (439,494) (2,174)
Balance, shares at Dec. 31, 2024 135,537 36,913        
Stock-based compensation 1,666 1,666
Unrealized foreign exchange on intercompany loans (2,380) (2,380)
Translation adjustment 2,385 2,385
Loss for the period (81) (81)
Issue costs on issuance of common stock, preferred stock and associated warrants on underwritten offering, net of expenses (248) (248)
Exercise of Pre-Funded Warrants
Exercise of Pre-Funded Warrants, shares   15,277        
Issue of common stock on Securities Purchase Agreement
Issue of common stock on Securities Purchase Agreement, shares   758        
Issue of Series C preferred stock in Securities Purchase Agreement $ 1 999 1,000
Issue of Series C preferred stock in Securities Purchase Agreement, shares 1,000,000          
Series C Preferred stock conversions $ (1) 1
Series C Preferred stock conversions, shares (1,000,000) 11,042        
Issue of Series D preferred stock in Securities Purchase Agreement $ 2 1,892 1,894
Issue of Series D preferred stock in Securities Purchase Agreement, shares 2,100,000          
Series D Preferred stock conversions $ (2) $ 1 1
Series D Preferred stock conversions, shares (1,745,262) 799,912        
Issue of Series E preferred stock in Securities Purchase Agreement $ 1 999 1,000
Issue of Series E preferred stock in Securities Purchase Agreement, shares 1,000,000          
Deconsolidation of foreign operation and transfer of accumulated translation adjustments to net income (loss) 886 (886)
Balances at Mar. 31, 2025 $ 1 $ 1 443,521 (440,461) 3,062
Balance, shares at Mar. 31, 2025 1,490,275 863,902        
Balances at Dec. 31, 2024 438,211 (891) (439,494) (2,174)
Balance, shares at Dec. 31, 2024 135,537 36,913        
Issue costs on issuance of common stock upon conversion of pre-funded warrants in underwritten offering   $ 72,108       6,290,213
Unrealized foreign exchange on intercompany loans           (2,380)
Translation adjustment           3,271
Loss for the period           (1,399)
Balances at Jun. 30, 2025 $ 3 $ 2 445,405 (441,779) 3,631
Balance, shares at Jun. 30, 2025 3,135,537 1,583,965        
Balances at Mar. 31, 2025 $ 1 $ 1 443,521 (440,461) 3,062
Balance, shares at Mar. 31, 2025 1,490,275 863,902        
Stock-based compensation 7 7
Unrealized foreign exchange on intercompany loans          
Translation adjustment          
Loss for the period (1,318) (1,318)
Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Private Placement, net of expenses
Issue of common stock and pre-funded warrants in Securities Purchase Agreement In Private Placement, net of expenses, shares   940        
Issue costs on issuance of common stock, preferred stock and associated warrants on underwritten offering, net of expenses 21 21
Series D Preferred stock conversions
Series D Preferred stock conversions, shares (354,738) 162,588        
Issue of Series F preferred stock in Securities Purchase Agreement $ 3 2,997 3,000
Issue of Series F preferred stock in Securities Purchase Agreement, shares 3,000,000          
Series E Preferred stock conversions $ (1) $ 1
Series E Preferred stock conversions, shares (1,000,000) 458,333        
Exercise of Warrants (1,100) (1,100)
Exercise of Warrants, shares   98,202        
Preferred stock dividends (41) (41)
Balances at Jun. 30, 2025 $ 3 $ 2 $ 445,405 $ (441,779) $ 3,631
Balance, shares at Jun. 30, 2025 3,135,537 1,583,965